Pan-cancer analysis and the oncogenic role of Glypican 1 in hepatocellular carcinoma.

Carcinoma, Hepatocellular / metabolism Glypicans / metabolism Humans Liver Neoplasms / metabolism Gene Expression Regulation, Neoplastic Cell Proliferation Cell Line, Tumor Apoptosis / genetics Signal Transduction Proto-Oncogene Proteins c-akt / metabolism
Apoptosis GPC-1 HCC Pan-cancer analysis Proliferation

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
09 Jul 2024
Historique:
received: 11 01 2024
accepted: 04 07 2024
medline: 10 7 2024
pubmed: 10 7 2024
entrez: 9 7 2024
Statut: epublish

Résumé

Recent studies indicate that Glypican 1 (GPC-1) is aberrantly expressed and plays a key role in certain cancers, but little is known in the hepatocellular carcinoma. Raw data from TCGA, GTEx and TIMER databases were utilized to comprehensively analyze GPC-1 expression landscape in pan-cancer, and the biological function of GPC-1 was investigated in liver cancer cells. The results revealed that GPC-1 is highly expressed in HCC, negatively correlated with survival, and also positively correlated with immune infiltration and clinical stage. Furthermore, GPC-1 promoted cell proliferation and inhibited apoptosis in the HCC cell lines. WGCNA analysis and HCCDB database revealed that Akt acted as a key molecule related to GPC-1, influencing biological functions and regulating cell malignant behaviors via the AKT signaling pathway. In conclusion, our findings provide a relatively comprehensive understanding of the oncogenic role of GPC-1 in HCC, implying that GPC-1 could serve as an innovative therapeutic target.

Identifiants

DOI: 10.1038/s41598-024-66838-9 PMID: 38982153
pubmed: 38982153
doi: 10.1038/s41598-024-66838-9
pii: 10.1038/s41598-024-66838-9
doi:

Substances chimiques

Glypicans 0
GPC1 protein, human 0
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15870

Subventions

Organisme : the Key R&D Project in Shaanxi Province
ID : 2024SF-YBXM-119
Organisme : the Key R&D Project in Shaanxi Province
ID : 2024SF-YBXM-309
Organisme : Fundamental Research Funds for the Central Universities
ID : No. xzy012023025
Organisme : National Natural Science Foundation of China
ID : No. 82103212

Informations de copyright

© 2024. The Author(s).

Références

Zughaibi, T. A., Suhail, M., Tarique, M. & Tabrez, S. Targeting PI3K/Akt/mTOR pathway by different flavonoids: A cancer chemopreventive approach. Int. J. Mol. Sci. https://doi.org/10.3390/ijms222212455 (2021).
doi: 10.3390/ijms222212455 pubmed: 34830339 pmcid: 8621356
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33. https://doi.org/10.3322/caac.21708 (2022).
doi: 10.3322/caac.21708 pubmed: 35020204
Zeng, J. S., Zeng, J. X., Huang, Y., Liu, J. F. & Zeng, J. H. The effect of adjuvant transarterial chemoembolization for hepatocellular carcinoma after liver resection based on risk stratification. Hepatob. Pancreat. Dis. 22, 482–489. https://doi.org/10.1016/j.hbpd.2022.07.007 (2023).
doi: 10.1016/j.hbpd.2022.07.007
Filmus, J. & Capurro, M. The role of glypicans in Hedgehog signaling. Matrix Biol. 35, 248–252. https://doi.org/10.1016/j.matbio.2013.12.007 (2014).
doi: 10.1016/j.matbio.2013.12.007 pubmed: 24412155
Filmus, J., Capurro, M. & Rast, J. Glypicans. Genome Biol. 9, 224. https://doi.org/10.1186/gb-2008-9-5-224 (2008).
doi: 10.1186/gb-2008-9-5-224 pubmed: 18505598 pmcid: 2441458
Awad, W. et al. Structural aspects of N-glycosylations and the C-terminal region in human Glypican-1. J. Biol. Chem. 290, 22991–23008. https://doi.org/10.1074/jbc.M115.660878 (2015).
doi: 10.1074/jbc.M115.660878 pubmed: 26203194 pmcid: 4645609
Svensson, G., Awad, W., Hakansson, M., Mani, K. & Logan, D. T. Crystal structure of N-glycosylated human glypican-1 core protein: Structure of two loops evolutionarily conserved in vertebrate glypican-1. J. Biol. Chem. 287, 14040–14051. https://doi.org/10.1074/jbc.M111.322487 (2012).
doi: 10.1074/jbc.M111.322487 pubmed: 22351761 pmcid: 3340175
Svensson, G., Hyrenius Wittsten, A., Linse, S. & Mani, K. The structural role of N-linked glycans on human glypican-1. Biochemistry 50, 9377–9387. https://doi.org/10.1021/bi200218s (2011).
doi: 10.1021/bi200218s pubmed: 21932778
Bishop, J. R., Schuksz, M. & Esko, J. D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446, 1030–1037. https://doi.org/10.1038/nature05817 (2007).
doi: 10.1038/nature05817 pubmed: 17460664
Kayed, H. et al. Correlation of glypican-1 expression with TGF-beta, BMP, and activin receptors in pancreatic ductal adenocarcinoma. Int. J. Oncol. 29, 1139–1148 (2006).
pubmed: 17016645
Duan, L., Hu, X. Q., Feng, D. Y., Lei, S. Y. & Hu, G. H. GPC-1 may serve as a predictor of perineural invasion and a prognosticator of survival in pancreatic cancer. Asian J. Surg. 36, 7–12. https://doi.org/10.1016/j.asjsur.2012.08.001 (2013).
doi: 10.1016/j.asjsur.2012.08.001 pubmed: 23270819
Zhou, C. Y. et al. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma. Cancer Med.-Us 7, 5525–5533. https://doi.org/10.1002/cam4.1833 (2018).
doi: 10.1002/cam4.1833
Zhu, J. et al. Identification of five glycolysis-related gene signature and risk score model for colorectal cancer. Front. Oncol. https://doi.org/10.3389/fonc.2021.588811 (2021).
doi: 10.3389/fonc.2021.588811 pubmed: 35712679 pmcid: 8739787
Yeh, M. C. et al. Targeted beta therapy of prostate cancer with Lu-177-labelled Miltuximab (R) antibody against glypican-1 (GPC-1). Ejnmmi Res. https://doi.org/10.1186/s13550-020-00637-x (2020).
doi: 10.1186/s13550-020-00637-x pubmed: 32382920 pmcid: 7206480
Truong, Q. et al. Glypican-1 as a biomarker for prostate cancer: isolation and characterization. J. Cancer 7, 1002–1009. https://doi.org/10.7150/jca.14645 (2016).
doi: 10.7150/jca.14645 pubmed: 27313791 pmcid: 4910593
Gao, J. J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal https://doi.org/10.1126/scisignal.2004088 (2013).
doi: 10.1126/scisignal.2004088 pubmed: 24170934 pmcid: 3969021
Vivian, J. et al. Toil enables reproducible, open source, big biomedical data analyses. Nat. Biotechnol. 35, 314–316. https://doi.org/10.1038/nbt.3772 (2017).
doi: 10.1038/nbt.3772 pubmed: 28398314 pmcid: 5546205
Nagy, A., Lanczky, A., Menyhart, O. & Gyorffy, B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci. Rep. 8, 9227. https://doi.org/10.1038/s41598-018-27521-y (2018).
doi: 10.1038/s41598-018-27521-y pubmed: 29907753 pmcid: 6003936
Wang, S. X. et al. UCSCXenaShiny: An R/CRAN package for interactive analysis of UCSC Xena data. Bioinformatics 38, 527–529. https://doi.org/10.1093/bioinformatics/btab561 (2022).
doi: 10.1093/bioinformatics/btab561 pubmed: 34323947
Li, T. W. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509–W514. https://doi.org/10.1093/nar/gkaa407 (2020).
doi: 10.1093/nar/gkaa407 pubmed: 32442275 pmcid: 7319575
Burgel, P. R. et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur. Respir. J. 36, 531–539. https://doi.org/10.1183/09031936.00175109 (2010).
doi: 10.1183/09031936.00175109 pubmed: 20075045
Chandrashekar, D. S. et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia 25, 18–27. https://doi.org/10.1016/j.neo.2022.01.001 (2022).
doi: 10.1016/j.neo.2022.01.001 pubmed: 35078134 pmcid: 8788199
Lian, Q. Y. et al. HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas. Genom. Proteom. Bioinf. 16, 269–275. https://doi.org/10.1016/j.gpb.2018.07.003 (2018).
doi: 10.1016/j.gpb.2018.07.003
Dennis, G. Jr. et al. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 4, P3 (2003).
doi: 10.1186/gb-2003-4-5-p3 pubmed: 12734009
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucl. Acids Res. 45, D353–D361. https://doi.org/10.1093/nar/gkw1092 (2017).
doi: 10.1093/nar/gkw1092 pubmed: 27899662
Mu, Y. et al. Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic cancer. Aging-Us 12, 19585–19596. https://doi.org/10.18632/aging.103918 (2020).
doi: 10.18632/aging.103918
Tsujii, S. et al. Glypican-1 is a novel target for stroma and tumor cell dual-targeting antibody-drug conjugates in pancreatic cancer. Mol. Cancer Ther. 20, 2495–2505. https://doi.org/10.1158/1535-7163.Mct-21-0335 (2021).
doi: 10.1158/1535-7163.Mct-21-0335 pubmed: 34583978
Matsuda, K. et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 61, 5562–5569 (2001).
pubmed: 11454708
Filmus, J. & Selleck, S. B. Glypicans: Proteoglycans with a surprise. J. Clin. Invest. 108, 497–501. https://doi.org/10.1172/JCI13712 (2001).
doi: 10.1172/JCI13712 pubmed: 11518720 pmcid: 209407
Pan, J. J. & Ho, M. Role of glypican-1 in regulating multiple cellular signaling pathways. Am. J. Physiol.-Cell Ph. 321, C846–C858. https://doi.org/10.1152/ajpcell.00290.2021 (2021).
doi: 10.1152/ajpcell.00290.2021
Wang, S., Qiu, Y. D. & Bai, B. The expression, regulation, and biomarker potential of glypican-1 in cancer. Front. Oncol. https://doi.org/10.3389/fonc.2019.00614 (2019).
doi: 10.3389/fonc.2019.00614 pubmed: 32257953 pmcid: 6951398
Melo, S. A. et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523, 177–182. https://doi.org/10.1038/nature14581 (2015).
doi: 10.1038/nature14581 pubmed: 26106858 pmcid: 4825698
Truong, Q. et al. Glypican-1 as a biomarker for prostate cancer: isolation and characterization. J Cancer 7, 1002–1009. https://doi.org/10.7150/jca.14645 (2016).
doi: 10.7150/jca.14645 pubmed: 27313791 pmcid: 4910593
Li, J. et al. GPC1 exosome and its regulatory miRNAs are specific markers for the detection and target therapy of colorectal cancer. J. Cell Mol. Med. 21, 838–847. https://doi.org/10.1111/jcmm.12941 (2017).
doi: 10.1111/jcmm.12941 pubmed: 28233416 pmcid: 5387162
Wang, J. Y. et al. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma. BMC Cancer 21, 462. https://doi.org/10.1186/s12885-021-08104-z (2021).
doi: 10.1186/s12885-021-08104-z pubmed: 33902495 pmcid: 8073913
Chen, G. Y., Wu, H., Zhang, L. & Wei, S. D. High glypican-1 expression is a prognostic factor for predicting a poor clinical prognosis in patients with hepatocellular carcinoma. Oncol. Lett. https://doi.org/10.3892/ol.2020.12058 (2020).
doi: 10.3892/ol.2020.12058 pubmed: 33552279 pmcid: 7798096
Cheng, F., Hansson, V. C., Georgolopoulos, G. & Mani, K. Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior. Oncotarget 14, 219–235. https://doi.org/10.18632/oncotarget.28388 (2023).
doi: 10.18632/oncotarget.28388 pubmed: 36944188 pmcid: 10030152
Li, J. et al. Glypican-1 promotes tumorigenesis by regulating the PTEN/Akt/beta-catenin signaling pathway in esophageal squamous cell carcinoma. Dig. Dis. Sci. 64, 1493–1502. https://doi.org/10.1007/s10620-019-5461-9 (2019).
doi: 10.1007/s10620-019-5461-9 pubmed: 30730015
Labbe, E. et al. Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer Res. 67, 75–84. https://doi.org/10.1158/0008-5472.CAN-06-2559 (2007).
doi: 10.1158/0008-5472.CAN-06-2559 pubmed: 17210685
de Moraes, G. F. A., Listik, E., Justo, G. Z., Vicente, C. M. & Toma, L. The Glypican proteoglycans show intrinsic interactions with Wnt-3a in human prostate cancer cells that are not always associated with cascade activation. BMC Mol. Cell. Biol. 22, 26. https://doi.org/10.1186/s12860-021-00361-x (2021).
doi: 10.1186/s12860-021-00361-x pubmed: 33947326 pmcid: 8097805

Auteurs

Li Cao (L)

Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.

Fang Li (F)

Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.

Shuang Cai (S)

Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.

Jinyuan Zhang (J)

Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.

Chen Guo (C)

Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.

Sadiq Ali (S)

Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.

Jing Zhou (J)

Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.

Xintao Jing (X)

Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.

Xiaofei Wang (X)

Biomedical Experimental Center of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China. wxiaofei@xjtu.edu.cn.
ORCID: 0000-0002-7704-4445

Yannan Qin (Y)

Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China. yannan159@xjtu.edu.cn.
Institute of Genetics and Development Biology, Translational Medicine Institute, Xi'an Jiaotong University, Xi'an, 710301, Shaanxi, People's Republic of China. yannan159@xjtu.edu.cn.
ORCID: 0000-0002-4810-7160

Fei Wu (F)

Comprehensive Breast Care Center, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710000, Shaanxi, People's Republic of China. wufei931105@xjtu.edu.cn.
Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China. wufei931105@xjtu.edu.cn.
Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710000, Shaanxi, People's Republic of China. wufei931105@xjtu.edu.cn.
ORCID: 0000-0001-5388-0003

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Carcinome hépatocellulaire › Pan-cancer analysis and the oncogenic role of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Glycoprotéines membranaires › Protéines liées au GPI › Glypicanes › Pan-cancer analysis and the oncogenic role of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Pan-cancer analysis and the oncogenic role of...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Pan-cancer analysis and the oncogenic role of...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › Pan-cancer analysis and the oncogenic role of...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Pan-cancer analysis and the oncogenic role of...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Pan-cancer analysis and the oncogenic role of...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Pan-cancer analysis and the oncogenic role of...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Pan-cancer analysis and the oncogenic role of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes c-akt › Pan-cancer analysis and the oncogenic role of...